The U.S. Food and Drug Administration (FDA) has approved Edurant (rilpivirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI)—the class of HIV meds that also includes Sustiva (efavirenz). Edurant is approved for people who haven’t taken HIV drugs before. Like all HIV meds, it’s taken with other drugs to make a complete combo. (Search “Edurant” at poz.com for more information.) And watch for a new tablet that will combine Edurant and Truvada (tenofovir/emtricitabine) for an all-in-one HIV regimen. It’s expected later this year.

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)